Cancer Therapy pp 235-242 | Cite as

Chemotherapy: Benefits and Limits

  • G. Falkson
Conference paper

Abstract

It is fortunate that the three treatment modalities for cancer, surgery, radiotherapy and chemotherapy (as given by a medical oncologist), are complementary and seldom compete with one another.

Keywords

Toxicity Doxorubicin Methotrexate Tamoxifen Cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bull JM, Tormey DC, Li S-H, Carbone PP, Falkson G, Blom J, Perlin E, Simon R (1978) A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657PubMedCrossRefGoogle Scholar
  2. van Dyk J J, Falkson HC, van der Merwe AM, Falkson G (1972) Unexpected toxicity in patients treated with iphosphamide. Cancer Res 32: 921–924PubMedGoogle Scholar
  3. Falkson G, van Dyk J J, Stapelberg R, Falkson HC (1982) Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. Cancer Chemother Pharmacol 9: 81–84PubMedCrossRefGoogle Scholar
  4. Falkson G, Gelman RS, Tormey DC, Cummings FJ, Carbone PP, Falkson HC (1985) The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 56: 219–224PubMedCrossRefGoogle Scholar
  5. Falkson G, Klein B, Falkson H (1985) Hematological toxicity: experience with anthracyclines and anthracenes. Exp Hematol [Suppl 16] 13: 64–71Google Scholar
  6. Falkson G, Gelman RS, Pretorius FJ (1986) Age as a prognostic factor in recurrent breast cancer. J Clin Oncol 4 (5): 663–671PubMedGoogle Scholar
  7. Falkson G, Gelman RS, Glick JH (1987) The induction efficiency of dibromodulcitol, adriamycin, vincristine, tamoxifen and fluoxymesterone in the treatment of patients with metastatic breast cancer. Proc Am Soc Clin Oncol (abstr) 6: 49Google Scholar
  8. Falkson G, Gelman RS, Tormey DC, Falkson CI, Wolter JM, Cummings FJ (1987) Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: An Eastern Cooperative Oncology Group study. J Clin Oncol 5 (6): 881–889PubMedGoogle Scholar
  9. Falkson G, Vorobiof DA (1987) Intranasal buserelin in the treatment of advanced prostatic cancer: a phase II trial. J Clin Oncol 5 (9): 1419–1423PubMedGoogle Scholar
  10. Loprinzi CL, Tormey DC, Rasmussen P, Falkson G, Davis TE, Falkson HC, Chang AYC (1986) Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol 4 (1): 46–56PubMedGoogle Scholar
  11. Taylor SG, Gelman RS, Falkson G, Cummings FJ (1986) Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104: 455–461PubMedGoogle Scholar
  12. Tormey DC, Simon R, Falkson G, Bull J, Band P, Perlin E, Blom J (1977) Evaluation of adriamycin and dibromodulcitol in metastatic breast carcinoma. Cancer Res 37: 529–534PubMedGoogle Scholar
  13. Tormey DC, Falkson G, Simon RM, Blom J, Bull JM, Lippman ME, Li S-H, Cassidy JG, Falkson HC (1979) A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. Cancer Clin Trials 2: 247–256Google Scholar
  14. Tormey DC, Falkson G, Crowley J, Falkson HC, Voelkel J, Davis TE (1982) Dibromodulcitol and adriamycin ±tamoxifen in advanced breast cancer. Am J Clin Oncol (CCT) 5: 33–39Google Scholar
  15. Tormey D, Gelman R, Falkson G (1983) Prospective evaluation of rotating chemotherapy in advanced breast cancer: An Eastern Cooperative Oncology Group trial. Am J Clin Oncol (CCT) 6: 1–18Google Scholar
  16. Vorobiof DA, Iturralde M, Falkson G (1985) Assessment of ventricular function by radionuclide angiography in patients receiving 4’epidoxorubicin and mitoxantrone. Cancer Chemother Pharmacol 15: 253–257PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1989

Authors and Affiliations

  • G. Falkson
    • 1
  1. 1.Department of Medical OncologyUniversity of PretoriaPretoriaRepublic of South Africa

Personalised recommendations